Results 191 to 200 of about 19,727 (209)

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

New England Journal of Medicine, 2014
Kris V Kowdley, K Rajender Reddy, Eric Lawitz   +2 more
exaly  

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

Lancet, The, 2014
Eric Lawitz
exaly  

Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection

New England Journal of Medicine, 2014
Mark S Sulkowski, K Rajender Reddy, Eric Lawitz   +2 more
exaly  

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection

New England Journal of Medicine, 2015
Jordan Feld, Tarik Asselah, Armando Abergel   +2 more
exaly  

Sofosbuvir

Reactions Weekly, 2015
openaire   +2 more sources

Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options

New England Journal of Medicine, 2013
Mark S Sulkowski, Eric Lawitz, Keyur Patel   +2 more
exaly  

Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

New England Journal of Medicine, 2015
Graham R Foster, Nezam Afdhal, Stuart K Roberts   +2 more
exaly  

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis

New England Journal of Medicine, 2015
Michael Curry, Jonathan M Fenkel, K Rajender Reddy   +2 more
exaly  

Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

New England Journal of Medicine, 2014
Stefan Zeuzem, Alessandra Mangia, Robert Flisiak   +2 more
exaly  

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

New England Journal of Medicine, 2017
Stuart C Gordon, Curtis Cooper, Myron Tong   +2 more
exaly